Introduction
Recent studies in animal models and cell culture studies have demonstrated that (as in mineralizing bone) vascular calcification must be actively inhibited by physiological function of resident cells (VSMCs and endothelial cells) and infiltrating cells (tissue macrophages). Characterization of targeted or naturally occurring mutations of a variety of bone and cartilage associated genes in mice has identified 11 different inhibitors of vascular calcification in vivo
. One of these inhibitors is the nucleotide pyrophosphatase/phosphodiesterase family member NPP1, since inborn deficiency of NPP1 is associated with calcification of arteries in mice and human beings [13] .
NPP1 is a major generator of extracellular inorganic pyrophosphate (PPi) in cartilage and a variety of other tissues [14, 15] . PPi potently inhibits hydroxyapatite crystal deposition and growth and regulates cell differentiation processes. The physiologic role of NPP1-mediated PPi generation in tissue calcification has come to light recently. First, an inactivating NPP1 mutation was linked to the hypermineralizing phenotype of ttw/ttw mice [15] . A similar phenotype is found in NPP1-knockout mice. In the aorta of these mice, hydroxyapatite crystals are deposited in the medial layer at the level of the internal elastic lamina. In human beings, inactivating mutations of ENPP1 are associated with generalized arterial calcification of infancy, a spontaneous and frequently lethal form of widely disseminated arterial media calcification [16] . [8, 17, 18] . Thus 
Polymorphisms of the ENPP1 gene have been associated with increased risk for myocardial infarction and earlier onset of peripheral arterial disease
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Occurrence and distribution of NPP1 and OPN in carotid plaques
Sections of plaque samples were analysed by immunofluorescence with respect to the expression and distribution of NPP1 and OPN in different plaques with various degrees of calcification (Figs 4-6).
In non-calcified plaques NPP1 was detected mainly in the media. In the non-calcified core region of a plaque (Fig. 4) , few NPP1 expressing cells were found (Fig. 4E, F) . In moderately calcified areas of the plaque (Fig. 5 (Fig. 5E, F) . In the media NPP1 colocalized with smooth muscle cells (Fig. 5G, H) . In the severely calcified plaque (Fig. 6 ) NPP1 was found in the acellular matrix of the non-calcified core area with only few expressing cells (Fig. 6E,  F) . OPN immunolabel gradually increased with progressing plaque calcification. In the uncalcified plaque (Fig. 4I, J) (Fig. 5I, J) . OPN was particularly strongly expressed in the acellular severely calcified areas of the plaque core (Fig. 6I, J 
) NPP1 was detected in the media and in intimal regions adjacent to the media
Calcification of atherosclerotic plaques and age
As shown in the present study, age correlated with the degree of calcification of atheromatous carotids in patients with proven calcification of the atheroma. This is in line with previous studies showing that, in patients with coronary heart disease and atherosclerosis, the extent of calcification highly correlates with age and mortality [7] . In carotid plaques, destabilization and thus fatal ischemic events have been associated with increased deposition of calcified matrix vesicles and microcalcifications [21] . In patients with end-stage renal disease the coronary calcium score increased with age [7] . Also, the presence of calcium in renal arteries was significantly associated with age [22] . To our knowledge, our investigations represent the first study confirming this association also in carotid atheromatous plaques. [16, 23, 24] . NPP1 levels and activity are reduced or even deficient in patients with generalized arterial calcification of infancy, a disorder caused by mutations in the ENPP1 gene [16, 23] . Moreover, ENPP1 polymorphisms have been associated with insulin resistance and atherogenic phenotypes, including coronary calcification and myocardial infarction [17, 18, 25] . The pathogenic mechanism underlying this link is most likely to be on the one hand a consequence of systemic abnormalities, which are associated to insulin resistance, such as arterial hypertension, obesity and dyslipidaemia [26] . On the other hand, atherosclerosis may derive secondary to a direct deleterious effect of impaired insulin signalling on the endothelium leading to reduced insulin-stimulated nitric oxide release and decreased vasodilatation [27] . However, these systemic effects, which are associated with increased NPP1 plasma levels interfering with insulin signalling [28] , were beyond the scope of our study. [29] and OPN [29, 30] , the expression of which has been found to correlate with increasing plaque calcification. [31] [32] [33] . Typically, OPN is associated with mineralized deposits in human atherosclerotic plaques [33] . Reportedly, OPN serum levels are elevated in patients with carotid stenosis and have been discussed as potential markers of vulnerable carotid plaques [34] . Taken [29, 30] . 
Expression of inhibitors of calcification in calcified atherosclerotic plaques
Expression of inhibitors of calcification and risk factors of atherosclerosis
